BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sussman CR, Wang X, Chebib FT, Torres VE. Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling. Cell Signal 2020;72:109649. [PMID: 32335259 DOI: 10.1016/j.cellsig.2020.109649] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou X, Torres VE. Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling. Front Mol Biosci 2022;9:981963. [DOI: 10.3389/fmolb.2022.981963] [Reference Citation Analysis]
2 Hansen JN, Kaiser F, Leyendecker P, Stüven B, Krause JH, Derakhshandeh F, Irfan J, Sroka TJ, Preval KM, Desai PB, Kraut M, Theis H, Drews AD, De-Domenico E, Händler K, Pazour GJ, Henderson DJP, Mick DU, Wachten D. A cAMP signalosome in primary cilia drives gene expression and kidney cyst formation. EMBO Rep 2022;23:e54315. [PMID: 35695071 DOI: 10.15252/embr.202154315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Centrone M, Ranieri M, Di Mise A, D’agostino M, Venneri M, Ferrulli A, Valenti G, Tamma G. AQP2 trafficking in health and diseases: an updated overview. The International Journal of Biochemistry & Cell Biology 2022. [DOI: 10.1016/j.biocel.2022.106261] [Reference Citation Analysis]
4 Tsukamoto S, Urate S, Yamada T, Azushima K, Yamaji T, Kinguchi S, Uneda K, Kanaoka T, Wakui H, Tamura K. Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2022;13:885457. [PMID: 35662736 DOI: 10.3389/fphar.2022.885457] [Reference Citation Analysis]
5 Scholz JK, Kraus A, Lüder D, Skoczynski K, Schiffer M, Grampp S, Schödel J, Buchholz B. Loss of Polycystin-1 causes cAMP-dependent switch from tubule to cyst formation. iScience 2022;25:104359. [DOI: 10.1016/j.isci.2022.104359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Park NH. The Chromosomes and the Kidney. Physician Assistant Clinics 2022. [DOI: 10.1016/j.cpha.2021.11.007] [Reference Citation Analysis]
7 Lonardo MS, Guida B, Cacciapuoti N, Di Lauro M, Cataldi M. ADULT DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROTOTYPICAL DISEASE FOR PHARMANUTRITION INTERVENTIONS. PharmaNutrition 2022. [DOI: 10.1016/j.phanu.2022.100294] [Reference Citation Analysis]
8 Di Mise A, Wang X, Ye H, Pellegrini L, Torres VE, Valenti G. Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB J 2021;35:e21874. [PMID: 34486176 DOI: 10.1096/fj.202100774R] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Stokman MF, Saunier S, Benmerah A. Renal Ciliopathies: Sorting Out Therapeutic Approaches for Nephronophthisis. Front Cell Dev Biol 2021;9:653138. [PMID: 34055783 DOI: 10.3389/fcell.2021.653138] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Sholokh A, Klussmann E. Local cyclic adenosine monophosphate signalling cascades-Roles and targets in chronic kidney disease. Acta Physiol (Oxf) 2021;232:e13641. [PMID: 33660401 DOI: 10.1111/apha.13641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Ramalingam H, Kashyap S, Cobo-Stark P, Flaten A, Chang CM, Hajarnis S, Hein KZ, Lika J, Warner GM, Espindola-Netto JM, Kumar A, Kanchwala M, Xing C, Chini EN, Patel V. A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease. Cell Metab 2021;33:1234-1247.e7. [PMID: 33852874 DOI: 10.1016/j.cmet.2021.03.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wachten D, Mick DU. Signal transduction in primary cilia - analyzing and manipulating GPCR and second messenger signaling. Pharmacol Ther 2021;224:107836. [PMID: 33744260 DOI: 10.1016/j.pharmthera.2021.107836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Gong X, Tao J, Wang Y, Wu J, An J, Meng J, Wang X, Chen Y, Zou J. Total barley maiya alkaloids inhibit prolactin secretion by acting on dopamine D2 receptor and protein kinase A targets. J Ethnopharmacol 2021;273:113994. [PMID: 33711439 DOI: 10.1016/j.jep.2021.113994] [Reference Citation Analysis]
14 Aukema HM. Prostaglandins as potential targets for the treatment of polycystic kidney disease. Prostaglandins Leukot Essent Fatty Acids 2021;164:102220. [PMID: 33285393 DOI: 10.1016/j.plefa.2020.102220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Song X, Tsakiridis E, Steinberg GR, Pei Y. Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease. Cellular Signalling 2020;73:109704. [DOI: 10.1016/j.cellsig.2020.109704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]